Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection (Q27490911)

22 June 2017

title

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection (English)

1 reference

22 June 2017

1 reference

1 reference

11

Keith R Jerome

1 reference

22 June 2017

Chihiro Morishima

1

1 reference

22 June 2017

Margaret C Shuhart

2

1 reference

22 June 2017

Chia C Wang

3

1 reference

22 June 2017

Denise M Paschal

4

1 reference

22 June 2017

Minjun C Apodaca

5

1 reference

22 June 2017

Yanze Liu

6

1 reference

22 June 2017

Derek D Sloan

7

1 reference

22 June 2017

Tyler N Graf

8

1 reference

22 June 2017

Nicholas H Oberlies

9

1 reference

22 June 2017

David Y-W Lee

10

1 reference

22 June 2017

Stephen J Polyak

12

1 reference

22 June 2017

language of work or name

English

0 references

publication date

24 September 2009

1 reference

22 June 2017

1 reference

22 June 2017

volume

138

1 reference

22 June 2017

issue

2

1 reference

22 June 2017

page(s)

671-81, 681.e1-2

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

22 June 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Anticancer potential of silymarin: from bench to bed side.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Immunopathogenesis in hepatitis C virus cirrhosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Projecting future complications of chronic hepatitis C in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Milk thistle for the treatment of liver disease: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Use of complementary and alternative medicine in patients with liver disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

The use of silymarin in the treatment of liver diseases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Pharmacokinetic studies with silymarin in human serum and bile.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Gram-Scale Purification of Flavonolignan Diastereoisomers from Silybum marianum (Milk Thistle) Extract in Support of Preclinical in vivo Studies for Prostate Cancer Chemoprevention

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Silibinin protects mice from T cell-dependent liver injury

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Progression of fibrosis in chronic hepatitis C.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

The long-term pathological evolution of chronic hepatitis C.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2819600

Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19782083

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1053/J.GASTRO.2009.09.021

1 reference

22 June 2017

0 references

1 reference